Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This work represents a key milestone in the company's chemistry, manufacturing and controls (CMC) strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The effort is being conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors.
For more information, visit the company's website at https://oncoinnovations.com/.
This announcement is significant as it moves ONC010 closer to clinical testing. The development of a scalable manufacturing process is crucial for ensuring consistent drug supply for trials and eventual commercialization. For investors and the oncology community, progress in CMC activities often signals a company's readiness to advance its pipeline, potentially impacting timelines and valuation.
The full press release is available at https://nnw.fm/kfFWv.
